Virucidal efficacy of povidone-iodine-containing disinfectants

Authors


Andreas Sauerbrei, Jena University Hospital, Institute of Virology and Antiviral Therapy, Hans-Knoell-Strasse 2, D-07745 Jena, Germany. E-mail: Andreas.Sauerbrei@med.uni-jena.de

Abstract

Aims:  The objective of this study was to evaluate virucidal efficacy of the commercially available povidone-iodine formulations Betaisodona® solution and Betaseptic Mundipharma® (Mundipharma).

Methods and Results:  The quantitative suspension test for virucidal testing of biocides according to the German guideline was used as method. The use of Betaisodona® solution resulted in virucidal efficacy, corresponding to ≥104-fold reduction in viral titre, against vaccinia virus, bovine viral diarrhoea virus and polyomavirus SV40 within 0·5 min and adenovirus type 5 within 3–5 min without and with organic load. For inactivation of the most resistant poliovirus type 1, a time interval of ≥60 min was needed. By contrast, Betaseptic Mundipharma® inactivated significantly all model viruses for virucidal testing including poliovirus type 1 within 5 min independently from the addition of proteins.

Conclusions:  Betaisodona® solution shows a good efficacy against enveloped model viruses as well as against some nonenveloped human viruses, e.g. adenovirus and polyomavirus. Betaseptic Mundipharma® has an excellent virucidal efficacy including the inactivation of the most resistent poliovirus type 1.

Significance and Impact of the Study:  The findings of this study make Betaseptic Mundipharma® suitable for virucidal disinfection of the skin within short time intervals.

Ancillary